![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CLCN5 |
Gene summary for CLCN5 |
![]() |
Gene information | Species | Human | Gene symbol | CLCN5 | Gene ID | 1184 |
Gene name | chloride voltage-gated channel 5 | |
Gene Alias | CLC5 | |
Cytomap | Xp11.23 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A8K4H5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1184 | CLCN5 | HCC1_Meng | Human | Liver | HCC | 3.78e-37 | 1.08e-01 | 0.0246 |
1184 | CLCN5 | HCC2 | Human | Liver | HCC | 4.65e-06 | 2.42e+00 | 0.5341 |
1184 | CLCN5 | S016 | Human | Liver | HCC | 2.65e-05 | 2.98e-01 | 0.2243 |
1184 | CLCN5 | S028 | Human | Liver | HCC | 3.50e-13 | 6.22e-01 | 0.2503 |
1184 | CLCN5 | S029 | Human | Liver | HCC | 1.43e-11 | 6.77e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19026007 | Liver | HCC | proton transmembrane transport | 87/7958 | 157/18723 | 7.27e-04 | 4.42e-03 | 87 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLCN5 | SNV | Missense_Mutation | novel | c.1702A>C | p.Thr568Pro | p.T568P | P51795 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR |
CLCN5 | SNV | Missense_Mutation | c.1933N>A | p.Glu645Lys | p.E645K | P51795 | protein_coding | deleterious(0.04) | probably_damaging(0.987) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
CLCN5 | SNV | Missense_Mutation | c.469N>A | p.Glu157Lys | p.E157K | P51795 | protein_coding | deleterious(0.03) | possibly_damaging(0.52) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CLCN5 | SNV | Missense_Mutation | c.707G>A | p.Cys236Tyr | p.C236Y | P51795 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CLCN5 | SNV | Missense_Mutation | rs782001528 | c.1475N>G | p.Val492Gly | p.V492G | P51795 | protein_coding | tolerated(0.21) | benign(0.006) | TCGA-E2-A1L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
CLCN5 | SNV | Missense_Mutation | novel | c.814N>A | p.Val272Met | p.V272M | P51795 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-LL-A6FR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CLCN5 | insertion | Nonsense_Mutation | novel | c.1426_1427insACATCATTTAGATGGTGAACAAATAGGCCTAGAAATTCAAAT | p.Arg476delinsHisIleIleTerMetValAsnLysTerAlaTerLysPheLysCys | p.R476delinsHII*MVNK*A*KFKC | P51795 | protein_coding | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
CLCN5 | insertion | In_Frame_Ins | novel | c.2096_2097insTGACAAGCAAGTGGGTGGCAGATGCTCTTGGGCGGG | p.Gln699delinsHisAspLysGlnValGlyGlyArgCysSerTrpAlaGly | p.Q699delinsHDKQVGGRCSWAG | P51795 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CLCN5 | SNV | Missense_Mutation | novel | c.2273N>C | p.Phe758Ser | p.F758S | P51795 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CLCN5 | SNV | Missense_Mutation | rs782817681 | c.1243N>T | p.Arg415Trp | p.R415W | P51795 | protein_coding | deleterious(0) | possibly_damaging(0.653) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |